Literature DB >> 25492965

Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.

Jonathan W Haskins1, Don X Nguyen1, David F Stern2.   

Abstract

The receptor tyrosine kinase ERBB4, a member of the epidermal growth factor receptor (EGFR) family, is unusual in that ERBB4 can undergo intramembrane proteolysis, releasing a soluble intracellular domain (ICD) that modulates transcription in the nucleus. We found that ERBB4 activated the transcriptional coactivator YAP, which promotes organ and tissue growth and is inhibited by the Hippo tumor-suppressor pathway. Overexpressing ERBB4 in cultured mammary epithelial cells or adding the ERBB4 ligand neuregulin 1 (NRG1) to breast cancer cell cultures promoted the expression of genes regulated by YAP, such as CTGF. Knocking down YAP or ERBB4 prevented the induction of CTGF expression by NRG1, as did treating cells with the ERBB inhibitors lapatinib or erlotinib, which reduced ERBB4 cleavage. NRG1 stimulated YAP activity to an extent comparable to that of EGF (epidermal growth factor) or LPA (lysophosphatidic acid), known activators of YAP. NRG1 stimulated YAP-dependent cell migration in breast cancer cell lines. These observations connect the unusual nuclear function of a growth factor receptor with a mechanosensory pathway and suggest that NRG1-ERBB4-YAP signaling contributes to the aggressive behavior of tumor cells.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25492965      PMCID: PMC4648367          DOI: 10.1126/scisignal.2005770

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  62 in total

1.  Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level.

Authors:  Jasminka Omerovic; Eleonora M R Puggioni; Silvia Napoletano; Vincenzo Visco; Rocco Fraioli; Luigi Frati; Alberto Gulino; Maurizio Alimandi
Journal:  Exp Cell Res       Date:  2004-04-01       Impact factor: 3.905

2.  Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

Authors:  Teemu T Junttila; Maria Sundvall; Mikael Lundin; Johan Lundin; Minna Tanner; Pirkko Härkönen; Heikki Joensuu; Jorma Isola; Klaus Elenius
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

3.  Prognostic value of ERBB family mRNA expression in breast carcinomas.

Authors:  Ivan Bièche; Peter Onody; Sengül Tozlu; Keltouma Driouch; Michel Vidaud; Rosette Lidereau
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

4.  Gene expression profiling of ErbB receptor and ligand-dependent transcription.

Authors:  Dhara N Amin; Archibald S Perkins; David F Stern
Journal:  Oncogene       Date:  2004-02-19       Impact factor: 9.867

5.  Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types.

Authors:  R Srinivasan; R Poulsom; H C Hurst; W J Gullick
Journal:  J Pathol       Date:  1998-07       Impact factor: 7.996

6.  Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5.

Authors:  Weiwen Long; Kay-Uwe Wagner; K C Kent Lloyd; Nadine Binart; Jonathan M Shillingford; Lothar Hennighausen; Frank E Jones
Journal:  Development       Date:  2003-09-03       Impact factor: 6.868

7.  The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.

Authors:  Christopher C Williams; June G Allison; Gregory A Vidal; Matthew E Burow; Barbara S Beckman; Luis Marrero; Frank E Jones
Journal:  J Cell Biol       Date:  2004-11-08       Impact factor: 10.539

8.  ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation.

Authors:  F E Jones; T Welte; X Y Fu; D F Stern
Journal:  J Cell Biol       Date:  1999-10-04       Impact factor: 10.539

9.  Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality.

Authors:  Hester Tidcombe; Amy Jackson-Fisher; Kathleen Mathers; David F Stern; Martin Gassmann; Jon P Golding
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-24       Impact factor: 12.779

10.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.

Authors:  D M Abd El-Rehim; S E Pinder; C E Paish; J A Bell; R S Rampaul; R W Blamey; J F R Robertson; R I Nicholson; I O Ellis
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more
  64 in total

Review 1.  YAP and TAZ: a nexus for Hippo signaling and beyond.

Authors:  Carsten Gram Hansen; Toshiro Moroishi; Kun-Liang Guan
Journal:  Trends Cell Biol       Date:  2015-06-02       Impact factor: 20.808

2.  The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.

Authors:  Paula González-Alonso; Sandra Zazo; Ester Martín-Aparicio; Melani Luque; Cristina Chamizo; Marta Sanz-Álvarez; Pablo Minguez; Gonzalo Gómez-López; Ion Cristóbal; Cristina Caramés; Jesús García-Foncillas; Pilar Eroles; Ana Lluch; Oriol Arpí; Ana Rovira; Joan Albanell; Sander R Piersma; Connie R Jimenez; Juan Madoz-Gúrpide; Federico Rojo
Journal:  Cancers (Basel)       Date:  2020-04-29       Impact factor: 6.639

Review 3.  Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway.

Authors:  Ursula Ehmer; Julien Sage
Journal:  Mol Cancer Res       Date:  2015-10-02       Impact factor: 5.852

4.  The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration.

Authors:  Veera K Ojala; Anna M Knittle; Peppi Kirjalainen; Johannes A M Merilahti; Maarit Kortesoja; Denis Tvorogov; Katri Vaparanta; Shujun Lin; Jürgen Kast; Arto T Pulliainen; Kari J Kurppa; Klaus Elenius
Journal:  J Biol Chem       Date:  2020-06-19       Impact factor: 5.157

5.  The protective effect of betacellulin against acute pancreatitis is ERBB4 dependent.

Authors:  Kathrin Hedegger; Franziska Stumpf; Helmut Blum; Alexander Graf; Roland Michael Schmid; Marina Lesina; Hana Algül; Marlon Roberto Schneider; Maik Dahlhoff
Journal:  J Gastroenterol       Date:  2019-08-27       Impact factor: 7.527

6.  Endocardial Hippo signaling regulates myocardial growth and cardiogenesis.

Authors:  Stanley Artap; Lauren J Manderfield; Cheryl L Smith; Andrey Poleshko; Haig Aghajanian; Kelvin See; Li Li; Rajan Jain; Jonathan A Epstein
Journal:  Dev Biol       Date:  2018-05-01       Impact factor: 3.582

7.  Monopolar spindle-one-binder protein 2 regulates the activity of large tumor suppressor/yes-associated protein to inhibit the motility of SMMC-7721 hepatocellular carcinoma cells.

Authors:  Weicheng Zhang; Jingyuan Shen; Fengming Gu; Ying Zhang; Wenjuan Wu; Jiachun Weng; Yuexia Liao; Zijing Deng; Qing Yuan; Lu Zheng; Yu Zhang; Weigan Shen
Journal:  Oncol Lett       Date:  2018-02-05       Impact factor: 2.967

8.  Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.

Authors:  Cynthia Lopez-Haber; Laura Barrio-Real; Victoria Casado-Medrano; Marcelo G Kazanietz
Journal:  Mol Cell Biol       Date:  2016-07-14       Impact factor: 4.272

9.  Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor.

Authors:  Rebecca E Vargas; Vy Thuy Duong; Han Han; Albert Paul Ta; Yuxuan Chen; Shiji Zhao; Bing Yang; Gayoung Seo; Kimberly Chuc; Sunwoo Oh; Amal El Ali; Olga V Razorenova; Junjie Chen; Ray Luo; Xu Li; Wenqi Wang
Journal:  EMBO J       Date:  2019-11-29       Impact factor: 11.598

10.  Phosphorylation of Tyr188 in the WW domain of YAP1 plays an essential role in YAP1-induced cellular transformation.

Authors:  Ying-Wei Li; Jin Guo; He Shen; Jun Li; Nuo Yang; Costa Frangou; Kayla E Wilson; Yinglong Zhang; Ashley L Mussell; Marius Sudol; Amjad Farooq; Jun Qu; Jianmin Zhang
Journal:  Cell Cycle       Date:  2016-07-18       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.